- Home
- SHOT vs PASG Comparison
SHOT vs PASG Comparison
Compare SHOT & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- PASG
- Stock Information
- Founded
- SHOT 2018
- PASG 2017
- Country
- SHOT United States
- PASG United States
- Employees
- SHOT N/A
- PASG N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- PASG Health Care
- Exchange
- SHOT Nasdaq
- PASG Nasdaq
- Market Cap
- SHOT 30.4M
- PASG 31.1M
- IPO Year
- SHOT 2020
- PASG 2020
- Fundamental
- Price
- SHOT $0.31
- PASG $0.39
- Analyst Decision
- SHOT
- PASG Strong Buy
- Analyst Count
- SHOT 0
- PASG 3
- Target Price
- SHOT N/A
- PASG $7.67
- AVG Volume (30 Days)
- SHOT 7.1M
- PASG 323.8K
- Earning Date
- SHOT 08-13-2025
- PASG 08-07-2025
- Dividend Yield
- SHOT N/A
- PASG N/A
- EPS Growth
- SHOT N/A
- PASG N/A
- EPS
- SHOT N/A
- PASG N/A
- Revenue
- SHOT $573,336.00
- PASG N/A
- Revenue This Year
- SHOT N/A
- PASG N/A
- Revenue Next Year
- SHOT N/A
- PASG N/A
- P/E Ratio
- SHOT N/A
- PASG N/A
- Revenue Growth
- SHOT 69.32
- PASG N/A
- 52 Week Low
- SHOT $0.23
- PASG $0.26
- 52 Week High
- SHOT $1.77
- PASG $1.33
- Technical
- Relative Strength Index (RSI)
- SHOT 47.00
- PASG 48.43
- Support Level
- SHOT $0.23
- PASG $0.38
- Resistance Level
- SHOT $0.37
- PASG $0.52
- Average True Range (ATR)
- SHOT 0.05
- PASG 0.04
- MACD
- SHOT 0.01
- PASG -0.01
- Stochastic Oscillator
- SHOT 40.84
- PASG 11.03
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.